LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Accelerates Cancer Care Innovation with Liora Technologies Acquisition and Leadership Expansion
LIXT is advancing its lead compound LB-100 across different clinical programs aimed at difficult-to-treat cancers The company’s acquisition of Liora Technologies introduces a complementary therapy platform with recurring revenue potential These updates underscore LIXTE’s broader strategy: integrating drug development and med-tech innovation to redefine cancer treatment LIXTE Biotechnology (NASDAQ: LIXT) is executing a differentiated strategy in oncology, extending beyond traditional drug development into a more integrated and multi-dimensional approach to cancer care. With the company’s lead clinical candidate, LB-100, advancing through trials and the addition of Liora Technologies to its platform, they are positioning themselves at the nexus of pharmaceutical…